<DOC>
	<DOC>NCT01544894</DOC>
	<brief_summary>The purpose of this study was to compare compliance and efficacy of raloxifene and strontium ranelate in a group of women with postmenopausal osteoporosis.</brief_summary>
	<brief_title>Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis</brief_title>
	<detailed_description>OBJECTIVE: To compare the performance of raloxifene and strontium rannelate in the management of women with postmenopausal osteoporosis. DESIGN: Prospective, open label study. SETTING: University hospital menopause unit. PATIENTS: 80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or strontium ranelate (2g/d). Participants were followed for 1 year. MAIN OUTCOME MEASURE(S): Compliance with each regime. Secondary objectives were parameters of efficacy, including changes in bone mineral density and bone biochemical markers.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Strontium ranelate</mesh_term>
	<criteria>Postmenopausal women with densitometric osteoporosis Secondary osteoporosis</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Postmenopausal osteoporosis</keyword>
	<keyword>Compliance</keyword>
	<keyword>Bone mineral density</keyword>
	<keyword>Bonemarkers</keyword>
</DOC>